Limits...
To estimate the efficacy of 0.1% tacrolimus with Colgate Oraguard-B paste for the treatment of patients with symptomatic oral lichen planus.

Nisa SU, Saggu TK - Indian J Dent (2016 Jan-Mar)

Bottom Line: Sixty-five (43.33%) patients had marked resolution of their lesions, i.e., the size of the lesion was decreased.Fourteen (9.33%) patients had remission of lesion (reduction in burning sensation and size of lesion) in symptoms as recorded by the VAS.Topical tacrolimus ointment 0.1% in Oraguard-B paste is an effective treatment for different types of OLP.

View Article: PubMed Central - PubMed

Affiliation: Department of Oral Medicine and Radiology, Bharati Vidyapeeth Dental College and Hospital, Pune, Maharashtra, India.

ABSTRACT

Aim and objectives: To investigate the efficacy of 0.1% tacrolimus with Colgate Oraguard-B paste for the treatment of patients with oral lichen planus (OLP).

Materials and methods: One hundred and fifty patients with symptomatic OLP participated in the study, who had clinically and histopathologically proven OLP. In this study, patients were provided with 0.1% tacrolimus ointment with Colgate Oraguard-B paste as the study medication. Patients were asked to use the medication over the areas three times a day until resolution of the lesion. Patients were recalled to assess the drug response every 15 days. The duration of treatment ranged from 3 months to 4 months, with follow-up of 2 years and 6 months.

Statistical analysis: The Wilcoxon signed-rank test was performed, which is a nonparametric statistical hypothesis test for comparing two related samples, matched samples or repeated measurements on a single sample to assess whether their population mean ranks differ (i.e., it is a paired difference test). In our study, the pre- and post-Visual Analogue Scale (VAS) values were compared and the mean, standard deviation and P values were calculated.

Results: Of 150 patients, 71 (47.33%) patients had complete resolution of the lesion to the topical tacrolimus therapy. Sixty-five (43.33%) patients had marked resolution of their lesions, i.e., the size of the lesion was decreased. Fourteen (9.33%) patients had remission of lesion (reduction in burning sensation and size of lesion) in symptoms as recorded by the VAS.

Conclusion: Topical tacrolimus ointment 0.1% in Oraguard-B paste is an effective treatment for different types of OLP.

No MeSH data available.


Related in: MedlinePlus

Mechanism of action of tacrolimus
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4836094&req=5

Figure 1: Mechanism of action of tacrolimus

Mentions: The most widely accepted treatment is topical and systemic corticosteroids. Alternative treatments include retinoids, ultraviolet phototherapy, steroid-sparing agents (hydroxychloroquine, azathioprine, mycophenolate mofetil) and pimecrolimus.[8] Although the above-mentioned drugs have shown positive results in the treatment of OLP, resistance to treatment and a high risk of toxicities limit their use. Tacrolimus (FK506/Prograph; Fujisawa Inc., Deerfield, IL, USA) is an immunosuppressive agent currently available worldwide for the prevention of organ transplant rejection. In recent years, tacrolimus ointment 0.1% and cream 0.1% (Protopic; Fujisawa Inc.) have received FDA approval for the treatment of atopic dermatitis in children, as has pyoderma gangrenosum because of its clinical benefits and safety profile. Tacrolimus is 10–100-times as potent as cyclosporine in its ability to inhibit IL-2 mRNA synthesis, and it inhibits mediator release from basophils and mast cells. It inhibits enzyme calcineurin phosphatase activity, resulting in decreased IL-2 synthesis and secretion hence inhibiting T cell multiplication [Figure 1].[9] With such an insight, this investigation was performed to assess the efficacy of 0.1% tacrolimus ointment with Oraguard-B paste for the treatment of patients with symptomatic OLP. Colgate Oragard-B paste is a powerful reliever and mucoadhesive with a protective barrier to give your patients fast pain relief.[10]


To estimate the efficacy of 0.1% tacrolimus with Colgate Oraguard-B paste for the treatment of patients with symptomatic oral lichen planus.

Nisa SU, Saggu TK - Indian J Dent (2016 Jan-Mar)

Mechanism of action of tacrolimus
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4836094&req=5

Figure 1: Mechanism of action of tacrolimus
Mentions: The most widely accepted treatment is topical and systemic corticosteroids. Alternative treatments include retinoids, ultraviolet phototherapy, steroid-sparing agents (hydroxychloroquine, azathioprine, mycophenolate mofetil) and pimecrolimus.[8] Although the above-mentioned drugs have shown positive results in the treatment of OLP, resistance to treatment and a high risk of toxicities limit their use. Tacrolimus (FK506/Prograph; Fujisawa Inc., Deerfield, IL, USA) is an immunosuppressive agent currently available worldwide for the prevention of organ transplant rejection. In recent years, tacrolimus ointment 0.1% and cream 0.1% (Protopic; Fujisawa Inc.) have received FDA approval for the treatment of atopic dermatitis in children, as has pyoderma gangrenosum because of its clinical benefits and safety profile. Tacrolimus is 10–100-times as potent as cyclosporine in its ability to inhibit IL-2 mRNA synthesis, and it inhibits mediator release from basophils and mast cells. It inhibits enzyme calcineurin phosphatase activity, resulting in decreased IL-2 synthesis and secretion hence inhibiting T cell multiplication [Figure 1].[9] With such an insight, this investigation was performed to assess the efficacy of 0.1% tacrolimus ointment with Oraguard-B paste for the treatment of patients with symptomatic OLP. Colgate Oragard-B paste is a powerful reliever and mucoadhesive with a protective barrier to give your patients fast pain relief.[10]

Bottom Line: Sixty-five (43.33%) patients had marked resolution of their lesions, i.e., the size of the lesion was decreased.Fourteen (9.33%) patients had remission of lesion (reduction in burning sensation and size of lesion) in symptoms as recorded by the VAS.Topical tacrolimus ointment 0.1% in Oraguard-B paste is an effective treatment for different types of OLP.

View Article: PubMed Central - PubMed

Affiliation: Department of Oral Medicine and Radiology, Bharati Vidyapeeth Dental College and Hospital, Pune, Maharashtra, India.

ABSTRACT

Aim and objectives: To investigate the efficacy of 0.1% tacrolimus with Colgate Oraguard-B paste for the treatment of patients with oral lichen planus (OLP).

Materials and methods: One hundred and fifty patients with symptomatic OLP participated in the study, who had clinically and histopathologically proven OLP. In this study, patients were provided with 0.1% tacrolimus ointment with Colgate Oraguard-B paste as the study medication. Patients were asked to use the medication over the areas three times a day until resolution of the lesion. Patients were recalled to assess the drug response every 15 days. The duration of treatment ranged from 3 months to 4 months, with follow-up of 2 years and 6 months.

Statistical analysis: The Wilcoxon signed-rank test was performed, which is a nonparametric statistical hypothesis test for comparing two related samples, matched samples or repeated measurements on a single sample to assess whether their population mean ranks differ (i.e., it is a paired difference test). In our study, the pre- and post-Visual Analogue Scale (VAS) values were compared and the mean, standard deviation and P values were calculated.

Results: Of 150 patients, 71 (47.33%) patients had complete resolution of the lesion to the topical tacrolimus therapy. Sixty-five (43.33%) patients had marked resolution of their lesions, i.e., the size of the lesion was decreased. Fourteen (9.33%) patients had remission of lesion (reduction in burning sensation and size of lesion) in symptoms as recorded by the VAS.

Conclusion: Topical tacrolimus ointment 0.1% in Oraguard-B paste is an effective treatment for different types of OLP.

No MeSH data available.


Related in: MedlinePlus